antimicrobial resistance Dotaz Zobrazit nápovědu

Antimicrobial resistance - main facts -- Antimicrobial resistance 2 -- Surveillance of AMR in Europe Overview of antimicrobial resistance In Europe и -- WHO European Region 12 -- EU/EEA countries 27 -- Tripartite antimicrobial resistance country self-assessment (TeACSS) 2020-2021 questionnaire 130 -- Annex

Antimicrobial resistance (AMR) remains a major public health concern in the WHO European Region, with ...

Světová zdravotnická organizace. Regionální úřadovna pro Evropu
Autor Autorita
European Centre for Disease Prevention and Control
Autor Autorita

xxi, 136 stran : ilustrace, grafy

Antimicrobial resistance (AMR) remains a major public health concern in the WHO European Region, with estimates from the European Union/European Economic Area (EU/EEA) alone showing that each year more than 670 000 infections are due to bacteria resistant to antibiotics and approximately 33 000 people die as a direct consequence. This report is the first in a series published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe that includes AMR data from invasive isolates in Europe. The report shows that AMR is widespread in the WHO European Region, although the AMR situation varied widely depending on the bacterial species, antimicrobial group and geographical region. A north-to-south and west-to-east gradient was generally observed, with higher AMR percentages in the southern and eastern parts of Europe. Overall in the EU/EEA, AMR percentages for the bacterial species–antimicrobial group combinations under surveillance continue to be high, with carbapenem resistance in Escherichia coli and Klebsiella pneumoniae (K. pneumoniae) and vancomycin resistance in Enterococcus faecium showing a significant increase during 2016–2020. High percentages of resistance to third-generation cephalosporins and carbapenems in K. pneumoniae and high percentages of carbapenem-resistant Acinetobacter species and Pseudomonas aeruginosa in several countries in the European Region are of concern. Effectively tackling AMR in the WHO European Region requires greater efforts and investments.

Kniha

Challenges to tackling antimicrobial resistance : economic and policy responses

The health and economic burden of antimicrobial resistance / Driss Ait Ouakrim, Alessandro Cassini, Michele Tackling antimicrobial resistance in the community / Sarah Tonkin-Crine, Lucy Abel, Oliver van Hecke, Tackling antimicrobial resistance in the hospital sector / Rasmus Leistner, Inge Gyssens -- 5. The role of vaccines in combating antimicrobial resistance / Mark Jit, Ben Cooper -- 8. The role of civil society in tackling antimicrobial resistance / Anthony So, Reshma Ramachandran.

European Observatory on Health Systems and Policies

First published xxi, 250 stran : ilustrace ; 23 cm

Collected works that focus on the current changes in European health care systems and economic and health policies, with regards to antimicrobial resistance. Intended for professional public.

Konspekt
Veřejné zdraví a hygiena
NLK Obory
veřejné zdravotnictví
politologie, politika, zdravotní politika
farmacie a farmakologie

Časopis

Journal of global antimicrobial resistance

Amsterdam : Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer, 2013-

svazky : ilustrace

Kniha

Antimicrobial resistance : insights into control and treatment of complicated infections

Boston : Pharmacotherapy Publications, 2005

Pharmacotherapy, ISSN 0277-0008 vol. 25, no. 10, part 2, October 2005

S. 42-70 : il., tab. ; 28 cm

Článek

Antimicrobial resistance: Concerns of healthcare providers and people with CF

BACKGROUND: Chronic lung infections and their treatment pose risks for the development of antimicrobial ...

Journal of cystic fibrosis. 2021 ; 20 (3) : 407-412. [pub] 20200617

J Cyst Fibros
ISSN 1873-5010
Medvik
Zdroj

BACKGROUND: Chronic lung infections and their treatment pose risks for the development of antimicrobial resistance (AMR) in people with cystic fibrosis (PWCF). In this study, we evaluated the attitudes of healthcare providers' (HCP) and PWCF or their parents' toward AMR within the international CF community. METHODS: HCP and PWCF identified through listservs and CF-related organizations were asked to complete an AMR centered survey, with additional questions on antimicrobial stewardship (AMS) for HCP. Descriptive analyses are reported. RESULTS: The responding 443 HCP and 464 PWCF/Parents were from 30 and 25 countries, respectively. Sixty-two percent of HCP and 56% of PWCF stated they were "very concerned" about AMR, with Pseudomonas spp. and Burkholderia spp. considered the most concerning organisms for both HCP and PWCF/Parents. Non-tuberculous mycobacteria were of greater concern to HCP compared to PWCF/Parents. There was a discrepancy regarding AMR education to PWCF, with 80% of HCP stating having discussed this with PWCF/Parents, but only 50% of PWCF recalling such discussions. CONCLUSION: These results highlight that AMR is relevant to CF HCP and PWCF internationally, indicating that educational tools and research are warranted.